Australia - English - Department of Health (Therapeutic Goods Administration)

care quip - 10787 - chair, - a device designed to be sat upon by a human. it is typically constructed with a back and arm rests. it can be used, e.g. for medical treatment, examination, therapy, rehabilitation, or resting. the device may also have a variety of special features, e.g. a raise/lower or tilt/swivel function, and can be equipped with accessories, e.g. foot or head rests.

Australia - English - Department of Health (Therapeutic Goods Administration)

care quip - 36995 - trolley, - to transport and store therapeutic goods within the hospital/healthcare environment.

Australia - English - Department of Health (Therapeutic Goods Administration)

care quip - 10342 - bed, - a bed used in hospitals, institutions or home care upon which a patient rests or sleeps, or upon which a patient may undergo treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

nature's care manufacture pty limited - ubidecarenone, quantity: 150 mg - capsule, soft - excipient ingredients: white beeswax; glycerol; titanium dioxide; hydrogenated vegetable oil; sorbitol solution (70 per cent) (non-crystallising); purified water; iron oxide red; iron oxide yellow; soya oil; gelatin; iron oxide black - antioxidant/reduce free radicals formed in the body ; helps reduce/decrease free radical damage to body cells ; enhance/promote energy levels ; maintain/support energy levels ; maintain/support energy production ; maintain/support general health and wellbeing ; helps in the maintenance of healthy blood lipids/blood fats ; maintain/support cardiovascular system health ; maintain/support healthy cardiovascular system function ; maintain/support heart health ; maintain/support blood vessel health ; helps enhance/promote blood vessel health ; helps enhance/improve/promote/increase physical/exercise performance

Australia - English - Department of Health (Therapeutic Goods Administration)

nature's care manufacture pty limited - ubidecarenone, quantity: 150 mg - capsule, soft - excipient ingredients: glycerol; gelatin; iron oxide yellow; iron oxide black; soya oil; titanium dioxide; white beeswax; hydrogenated vegetable oil; purified water; iron oxide red; sorbitol solution (70 per cent) (non-crystallising) - antioxidant/reduce free radicals formed in the body ; helps reduce/decrease free radical damage to body cells ; enhance/promote energy levels ; maintain/support energy levels ; maintain/support energy production ; maintain/support general health and wellbeing ; helps in the maintenance of healthy blood lipids/blood fats ; maintain/support cardiovascular system health ; maintain/support healthy cardiovascular system function ; maintain/support heart health ; maintain/support blood vessel health ; helps enhance/promote blood vessel health ; helps enhance/improve/promote/increase physical/exercise performance

Australia - English - Department of Health (Therapeutic Goods Administration)

nature's care manufacture pty limited - ubidecarenone, quantity: 50 mg - capsule, soft - excipient ingredients: purified water; sorbitol solution (70 per cent) (non-crystallising); gelatin; glycerol; iron oxide black; soya oil; hydrogenated vegetable oil; iron oxide yellow; iron oxide red; titanium dioxide; white beeswax - antioxidant/reduce free radicals formed in the body ; helps reduce/decrease free radical damage to body cells ; enhance/promote energy levels ; maintain/support energy levels ; maintain/support energy production ; maintain/support general health and wellbeing ; helps in the maintenance of healthy blood lipids/blood fats ; maintain/support cardiovascular system health ; maintain/support healthy cardiovascular system function ; maintain/support heart health ; maintain/support blood vessel health ; helps enhance/promote blood vessel health ; helps enhance/improve/promote/increase physical/exercise performance

Australia - English - Department of Health (Therapeutic Goods Administration)

nature's care manufacture pty limited - ubidecarenone -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - ubidecarenone -

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole 2 mg - requip xl (ropinirole extended-release tablets) is indicated for the treatment of the signs and symptoms of idiopathic parkinson’s disease. none. pregnancy category c. there are no adequate and well-controlled studies using ropinirole in pregnant women. requip xl should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus. in animal reproduction studies, ropinirole has been shown to have adverse effects on embryo-fetal development, including teratogenic effects. treatment of pregnant rats with ropinirole during organogenesis resulted in decreased fetal body weight, increased fetal death, and digital malformations at 24, 36, and 60 times the mrhd, respectively. the combined administration of ropinirole at 8 times the mrhd and a clinically relevant dose of l-dopa to pregnant rabbits during organogenesis produced a greater incidence and severity of fetal malformations (primarily digit defects) than were seen in the offspring of rabbits treated with l-dopa alone. in a p

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole 1 mg - requip is indicated for the treatment of the signs and symptoms of idiopathic parkinson’s disease. the effectiveness of requip was demonstrated in randomized, controlled trials in patients with early parkinson’s disease who were not receiving concomitant l-dopa therapy as well as in patients with advanced disease on concomitant l-dopa (see clinical pharmacology: clinical trials). requip is indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). key diagnostic criteria for rls are: an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or night. difficulty falling asleep may frequently be associated with moderate-to-severe rls. requip is contraindicated for patients k